Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company provides the products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Revenue projections:

Revenue projections for ZYDUSLIFE
Revenue projections for ZYDUSLIFE

Zydus Lifesciences Limited's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.

Financial Ratios:

currentRatio 1.88500
forwardPE 22.20791
debtToEquity 12.20900
earningsGrowth -0.00400
revenueGrowth 0.18000
grossMargins 0.71868
operatingMargins 0.29227
trailingEps 44.94000
forwardEps 0.00000

A current ratio of 1.885 for ZYDUSLIFE implies that the company has ample liquidity to meet its short-term debts. ZYDUSLIFE's cash reserves and current assets should easily cover these obligations, highlighting its financial stability and ability to manage short-term liabilities.
ZYDUSLIFE's Forward PE is at a healthy level, meaning the stock price is aligned favorably with earnings. This suggests that the stock isn't overpriced, providing room for growth and making it an appealing option for investors looking to capitalize on potential future gains.
ZYDUSLIFE's low Debt-to-Equity ratio highlights its minimal reliance on debt, showing that the company is not over-leveraged. This contributes to lower financial risk and greater stability, giving ZYDUSLIFE a stronger position in managing its financial obligations.
Zydus Lifesciences Limited's positive gross and operating margins reflect strong profitability and operational efficiency. These metrics indicate the company's ability to control costs while maintaining healthy revenue, contributing to its solid financial performance.

Price projections:

Price projections for ZYDUSLIFE
Price projections for ZYDUSLIFE

Price projections for Zydus Lifesciences Limited have been gradually lowered, signaling reduced optimism among analysts. This downward adjustment suggests that the company may face challenges in meeting previous growth expectations.

Recommendation changes over time:

Recommendations trend for ZYDUSLIFE
Recommendations trend for ZYDUSLIFE


Analysts have maintained a buy bias for Zydus Lifesciences Limited, which could prompt investors to consider the stock as a viable investment. With this positive outlook, Zydus Lifesciences Limited is positioned as an attractive option for those looking to park their money in a stable and potentially lucrative company.